Investigating how Posaconazole works in cancer patients receiving chemotherapy or stem cell transplants
Official title: Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection
Run by Melbourne Health · NCT03717623 · Data updated 2026-11-12
This study is testing how well the antifungal drug Posaconazole works in adults getting chemotherapy or stem cell transplants to see if it can help prevent serious fungal infections.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Melbourne Health Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Parkville, Victoria) |
| Status | Recruiting |
| Started | August 1, 2019 |
| Main results expected | December 30, 2025 |
| Study ends | December 30, 2025 |
| Registry record updated | February 28, 2025 |
| Trial ID | NCT03717623 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adult hematology patients aged 18 and older who are receiving Posaconazole prophylaxis in an inpatient setting.
✕Probably not a fit
Patients who are unable to give informed consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to explore the pharmacokinetics of Posaconazole, an antifungal medication, in adult patients undergoing chemotherapy or stem cell transplants. Participants will receive oral Posaconazole as a standard prophylactic treatment against invasive fungal infections and will provide blood samples at specified intervals to monitor drug levels. The study will help determine how well the drug is absorbed and metabolized in this patient population, particularly in those who may experience complications such as malabsorption. The findings could inform dosing strategies and improve patient outcomes during cancer treatment.
Why it matters
Potential benefit: If successful, this study could enhance the effectiveness of antifungal prophylaxis in vulnerable cancer patients, potentially reducing the incidence of serious infections.
How similar studies have gone: Other studies have shown promising results in understanding the pharmacokinetics of antifungal agents in similar patient populations, suggesting that this approach is both relevant and potentially beneficial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult (≥18 years old) haematology patients receiving Posaconazole prophylaxis in the inpatient setting as standard of care. * Able to give informed consent. Exclusion Criteria: * Unable to give informed consent.
Where it's running
-
Melbourne Health
Parkville, Victoria, Australia Recruiting
Study contacts
- Study coordinator: Monica Slavin, Prof
- Email: monica.slavin@mh.org.au
- Phone: 61 3 9342 9403
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Levetiracetam Dosing in Critically Ill on CRRT
This study tests how levetiracetam behaves in the bodies of adults on continuous renal replacement therapy to help figure out the best dosing.
-
Trigonelline Monohydrate for NAD+ Metabolism in Healthy Adults
A small study in healthy adults tests whether taking trigonelline monohydrate by mouth for 4 weeks can change NAD+ levels and how the body handles the supplement, compared with NMN and placebo.
-
Cetuximab bioequivalence test in healthy men
This study tests whether a cetuximab injection is bioequivalent to Erbitux in healthy men to see if they behave the same in the body.
-
FUNGAL-P: A score to spot fungal pneumonia early in adults with pneumonia
Aimed at adults with pneumonia, this study tests a new score to help identify fungal pneumonia sooner so doctors can test appropriately and start antifungal treatment when needed.
-
How long-acting cabotegravir works for HIV prevention and how hormones might affect it
This study tests whether long-acting cabotegravir can prevent HIV and how endogenous or therapeutic hormones might change its levels in blood and genital tissues among adults.
-
GenSci142 as a vaginal treatment for bacterial vaginosis
This study tests whether GenSci142 given as vaginal doses is safe and may help BV patients aged 18–50 compared with clindamycin cream.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.